{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:43Z","timestamp":1792601443516,"version":"4.5.0"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/PR52669\/MED\/30\/2549\/2024"],"award-info":[{"award-number":["BT\/PR52669\/MED\/30\/2549\/2024"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["JCB\/2023\/000011"],"award-info":[{"award-number":["JCB\/2023\/000011"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EM\/SG\/Dev.Res\/114\/6828-2023 (EO. No. 169915)"],"award-info":[{"award-number":["EM\/SG\/Dev.Res\/114\/6828-2023 (EO. No. 169915)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154292","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:14:39Z","timestamp":1784042079000},"page":"154292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reprogramming tumor angiogenesis in breast cancer: Mechanisms, challenges, and future directions"],"prefix":"10.1016","volume":"831","author":[{"given":"Barnalee","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryendu","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0894-8571","authenticated-orcid":false,"given":"Samikshya","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinjan","family":"Khanra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-4033","authenticated-orcid":false,"given":"Gopal C.","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154292_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154292_bib4","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.154292_bib5","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154292_bib8","article-title":"Hypoxia in breast cancer-scientific translation to therapeutic and diagnostic clinical applications","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073765","article-title":"Anti-angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib11","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2026.154292_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071758","article-title":"Vasculogenic mimicry in breast cancer: clinical relevance and drivers","volume":"10","author":"Morales-Guadarrama","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154292_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12032-024-02477-4","article-title":"The potential of lenvatinib in breast cancer therapy","volume":"41","author":"Shang","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12885-023-11790-6","article-title":"A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.751578","article-title":"Non-coding RNAs in regulating tumor angiogenesis","volume":"9","author":"Song","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jjco\/hyt201","article-title":"Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials","volume":"44","author":"Fakhrejahani","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838133","article-title":"Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches","volume":"13","author":"Ayoub","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154292_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1215\/S1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib21","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.bbrc.2026.154292_bib22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1042\/BST0371233","article-title":"VEGFRs and Notch: a dynamic collaboration in vascular patterning","volume":"37","author":"Jakobsson","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbrc.2026.154292_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","article-title":"Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation","volume":"454","author":"Tammela","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154292_bib24","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1172\/JCI24311","article-title":"Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression","volume":"117","author":"Shawber","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154292_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","article-title":"Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis","volume":"445","author":"Hellstrom","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154292_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2040-2384-2-3","article-title":"Notch regulates the angiogenic response via induction of VEGFR-1","volume":"2","author":"Funahashi","year":"2010","journal-title":"J. Angiogenes Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib27","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1073\/pnas.0611206104","article-title":"Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting","volume":"104","author":"Lobov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154292_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2867-8-11","article-title":"Comparison of angiogenesis-related factor expression in primary tumor cultures under normal and hypoxic growth conditions","volume":"8","author":"Heinzman","year":"2008","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrc.2026.154292_bib29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1083\/jcb.200302047","article-title":"VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia","volume":"161","author":"Gerhardt","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.devcel.2008.12.009","article-title":"Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis","volume":"16","author":"Phng","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.devcel.2013.05.010","article-title":"In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular anastomosis","volume":"25","author":"Lenard","year":"2013","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/dbio.1996.9993","article-title":"VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane","volume":"176","author":"Wilting","year":"1996","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.leu.2403246","article-title":"Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo","volume":"18","author":"Crivellato","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154292_bib34","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","article-title":"VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells","volume":"18","author":"Asahara","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2026.154292_bib35","article-title":"Functional and biological role of endothelial precursor cells in tumour progression: a new potential therapeutic target in haematological malignancies","volume":"2016","author":"Reale","year":"2016","journal-title":"Stem Cell. Int."},{"key":"10.1016\/j.bbrc.2026.154292_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/path.4845","article-title":"Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models","volume":"241","author":"Bridgeman","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2026.154292_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.965277","article-title":"Tumor vessel co-option: the past & the future","volume":"12","author":"Cuypers","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115927","article-title":"Breast cancer cells-derived Von Willebrand Factor promotes VEGF-A-related angiogenesis through PI3K\/Akt-miR-205-5p signaling pathway","volume":"440","author":"Tao","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154292_bib40","article-title":"L1CAM, CA9, KLK6, HPN, and ALDH1A1 as potential serum markers in primary and metastatic colorectal cancer screening","volume":"10","author":"Tieng","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.bbrc.2026.154292_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.11.003","article-title":"Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2","volume":"482","author":"Pan","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154292_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41416-023-02509-2","article-title":"EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia","volume":"130","author":"Patel","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.102433","article-title":"STAMBPL1 activates the GRHL3\/HIF1A\/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer","volume":"13","author":"Fang","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.bbrc.2026.154292_bib44","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202500461R","article-title":"The RNA-binding proteins MCPIP2 and IGF2BP1 competitively modulate breast tumor angiogenesis by antagonizing VEGFA mRNA stability and expression","volume":"39","author":"Lu","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2026.154292_bib45","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41419-021-04102-y","article-title":"USP12 promotes breast cancer angiogenesis by maintaining midkine stability","volume":"12","author":"Sheng","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154292_bib46","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s12094-022-02918-4","article-title":"TNFAIP3 mediates FGFR1 activation-induced breast cancer angiogenesis by promoting VEGFA expression and secretion","volume":"24","author":"Gao","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-017-4102-2","article-title":"Angiopoietin pathway gene expression associated with poor breast cancer survival","volume":"162","author":"Ramanathan","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2026.154292_bib48","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3892\/ol.2020.11768","article-title":"ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2026.154292_bib49","article-title":"The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms","volume":"12","author":"Hu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib50","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41388-018-0592-6","article-title":"Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4","volume":"38","author":"Kolb","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154292_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00332-18","article-title":"Interleukin-8 activates breast cancer-associated adipocytes and promotes their Angiogenesis- and tumorigenesis-promoting effects","volume":"39","author":"Al-Khalaf","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/0008-5472.CAN-23-2640","article-title":"A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12967-018-1660-y","article-title":"Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling","volume":"16","author":"Parr","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib54","article-title":"Tumor necrosis factor-alpha (TNFalpha) stimulate triple-negative breast cancer stem cells to promote intratumoral invasion and neovasculogenesis in the liver of a xenograft model","volume":"11","author":"Narasimhan","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bbrc.2026.154292_bib55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1759-7714.14820","article-title":"Circ_0001667 accelerates breast cancer proliferation and angiogenesis through regulating CXCL10 expression by sponging miR-6838-5p","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10020-021-00338-8","article-title":"Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7\/EGFR\/AKT axis","volume":"27","author":"Lu","year":"2021","journal-title":"Mol Med"},{"key":"10.1016\/j.bbrc.2026.154292_bib57","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/2211-5463.13582","article-title":"Reduced FRG1 expression promotes angiogenesis via activation of the FGF2-mediated ERK\/AKT pathway","volume":"13","author":"Mukherjee","year":"2023","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbrc.2026.154292_bib58","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.7150\/thno.72404","article-title":"Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling","volume":"12","author":"Han","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154292_bib59","article-title":"PCDHB17P\/miR-145-3p\/MELK\/NF-kappaB feedback loop promotes metastasis and angiogenesis of breast cancer","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib60","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/febs.16605","article-title":"DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-kappaB-HIF1alpha axis","volume":"290","author":"Neeli","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.bbrc.2026.154292_bib61","first-page":"1","article-title":"Antiangiogenic mechanisms and factors in breast cancer treatment","volume":"15","author":"Castaneda-Gill","year":"2016","journal-title":"J. Carcinog."},{"key":"10.1016\/j.bbrc.2026.154292_bib62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301703","article-title":"Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells","volume":"9","author":"Indraccolo","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/rp.59.1.73","article-title":"Angiostatin and anti-angiogenic therapy in human disease","volume":"59","author":"Wahl","year":"2004","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/mthe.2000.0243","article-title":"Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice","volume":"3","author":"Scappaticci","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib66","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.92.10.4562","article-title":"Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas","volume":"92","author":"Singh","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154292_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib68","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbadis.2012.10.013","article-title":"Fibroblasts as architects of cancer pathogenesis","volume":"1832","author":"Marsh","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2026.154292_bib69","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s12672-025-03797-1","article-title":"Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","article-title":"Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression","volume":"31","author":"Cirri","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbrc.2026.154292_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib72","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1158\/0008-5472.CAN-13-2740","article-title":"Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties","volume":"74","author":"Augsten","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib73","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/sj.onc.1209168","article-title":"Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis","volume":"25","author":"Maeda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154292_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41420-023-01768-5","article-title":"BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer","volume":"10","author":"Lee","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbrc.2026.154292_bib75","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154292_bib76","first-page":"8150","article-title":"Involvement of breast cancer stem cells in tumor angiogenesis","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2026.154292_bib77","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/onc.2013.214","article-title":"miR-27a regulates endothelial differentiation of breast cancer stem like cells","volume":"33","author":"Tang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154292_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084256","article-title":"Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154292_bib79","article-title":"The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154292_bib80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphys.2013.00159","article-title":"Macrophages and chemokines as mediators of angiogenesis","volume":"4","author":"Owen","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2026.154292_bib82","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 macrophages stimulate tumor relapse after chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib83","doi-asserted-by":"crossref","first-page":"34758","DOI":"10.18632\/oncotarget.5325","article-title":"CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.154292_bib84","article-title":"Mouse modeling dissecting macrophage-breast cancer communication uncovered roles of PYK2 in macrophage recruitment and breast tumorigenesis","volume":"9","author":"Muller","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbrc.2026.154292_bib85","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","article-title":"Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity","volume":"24","author":"Casazza","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12935-022-02527-9","article-title":"Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway","volume":"22","author":"Radharani","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrc.2026.154292_bib87","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","article-title":"Macrophage diversity in cancer revisited in the era of single-cell omics","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbrc.2026.154292_bib88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/03602532.2022.2116033","article-title":"Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy","volume":"54","author":"Mohammadi","year":"2022","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbrc.2026.154292_bib89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10456-021-09785-7","article-title":"Vascular endothelial cell specification in health and disease","volume":"24","author":"Marziano","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2026.154292_bib90","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1158\/0008-5472.CAN-07-2126","article-title":"Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms","volume":"68","author":"Chakraborty","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib91","article-title":"TGF-beta1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib92","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1331355","article-title":"Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours","volume":"14","author":"Bigos","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib94","article-title":"Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity","volume":"3","author":"Ortmann","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib95","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ncb3330","article-title":"The ever-expanding role of HIF in tumour and stromal biology","volume":"18","author":"LaGory","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib96","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/0008-5472.CAN-19-1532","article-title":"HIF2-Induced long noncoding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis","volume":"80","author":"Niu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib97","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/onc.2013.171","article-title":"Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis","volume":"33","author":"Raja","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154292_bib98","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CMAR.S327621","article-title":"Hypoxic breast cancer cell-derived exosomal SNHG1 promotes breast cancer growth and angiogenesis via regulating miR-216b-5p\/JAK2 axis","volume":"14","author":"Dai","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tranon.2018.10.004","article-title":"Co-Expression of VEGF and IL-6 family cytokines is associated with decreased survival in HER2 negative breast cancer patients: subtype-specific IL-6 family cytokine-mediated VEGF secretion","volume":"12","author":"Tawara","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib101","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast cancer progression, diagnosis, and treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113861","article-title":"Targeting hypoxia-inducible factor-1alpha: a new strategy for triple-negative breast cancer therapy","volume":"156","author":"Liu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2026.154292_bib103","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1172\/JCI137552","article-title":"HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer","volume":"130","author":"de Heer","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154292_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41231-023-00135-x","article-title":"Expression of HIF-1\u03b1 and markers of angiogenesis and metabolic adaptation in molecular subtypes of breast cancer","volume":"8","author":"Farooq","year":"2023","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.bbrc.2026.154292_bib105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10238-024-01446-5","article-title":"Angiogenesis in breast cancer: insights and innovations","volume":"24","author":"Elayat","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311508","article-title":"Molecular mechanisms driving metastatic progression within the aged tumor microenvironment","volume":"26","author":"Kumar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib107","article-title":"Dual faces of angiogenesis: mechanisms and therapeutic applications, Biochimica et biophysica acta","volume":"1880","author":"Izadpanah","year":"2025","journal-title":"Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-019-1097-0","article-title":"HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer","volume":"21","author":"Jarman","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200302","article-title":"Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial","volume":"13","author":"Goussia","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154292_bib110","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-Overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/bcr589","article-title":"Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment","volume":"5","author":"Boudreau","year":"2003","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib112","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10549-023-06974-4","article-title":"Vessel size as a marker of survival in estrogen receptor positive breast cancer","volume":"200","author":"Milosevic","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2026.154292_bib113","first-page":"8742","article-title":"Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo","volume":"63","author":"Garvin","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2026.154292_bib115","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/jnci\/84.24.1875","article-title":"Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma","volume":"84","author":"Weidner","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2026.154292_bib116","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib117","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrc3726","article-title":"Hypoxia and the extracellular matrix: drivers of tumour metastasis","volume":"14","author":"Gilkes","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib118","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"issue":"Suppl 3","key":"10.1016\/j.bbrc.2026.154292_bib119","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.bbrc.2026.154292_bib120","first-page":"963","volume":"57","author":"Relf","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154292_bib122","article-title":"Emerging roles of angiopoietin-like 4 in human tumors","volume":"66","author":"Liu","year":"2025","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194638","article-title":"Angiogenic role of miR-20a in breast cancer","volume":"13","author":"Luengo-Gil","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154292_bib124","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2741\/s28","article-title":"Circulating endothelial cells as biomarkers for angiogenesis in tumor progression","volume":"1","author":"Martin-Padura","year":"2009","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.bbrc.2026.154292_bib125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.bjc.6602952","article-title":"Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer","volume":"94","author":"Furstenberger","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s43046-021-00072-6","article-title":"Anti-angiogenesis in cancer therapeutics: the magic bullet","volume":"33","author":"Oguntade","year":"2021","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2026.154292_bib127","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154292_bib128","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","article-title":"U.S. FDA drug approvals for breast cancer: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13058-020-01362-y","article-title":"Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial","volume":"22","author":"Quintela-Fandino","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","author":"Gion","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.20517\/2394-4722.2022.08","article-title":"Anti-angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential","volume":"8","author":"Polyxeni","year":"2022","journal-title":"J. Cancer Metast. Treatment"},{"key":"10.1016\/j.bbrc.2026.154292_bib132","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2077898","article-title":"Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy","volume":"11","author":"Petrazzuolo","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbrc.2026.154292_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib134","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11523-024-01067-8","article-title":"Anti-angiogenic tyrosine kinase inhibitor-related toxicities among cancer patients: a systematic review and meta-analysis","volume":"19","author":"Van Nguyen","year":"2024","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib135","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.62347\/KIVS3169","article-title":"Receptor tyrosine kinases in breast cancer treatment: unraveling the potential","volume":"14","author":"Qi","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4137\/BCBCR.S29268","article-title":"Everolimus in the treatment of metastatic breast cancer","volume":"9","author":"Royce","year":"2015","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.bbrc.2026.154292_bib137","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1038\/s41598-017-03728-3","article-title":"Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1","volume":"7","author":"Alshaker","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib138","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1634\/theoncologist.2018-0407","article-title":"Everolimus plus exemestane for hormone receptor-positive advanced breast cancer: a PAM50 intrinsic subtype analysis of BOLERO-2","volume":"24","author":"Prat","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2026.154292_bib139","doi-asserted-by":"crossref","first-page":"44563","DOI":"10.18632\/oncotarget.6310","article-title":"Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.154292_bib140","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib141","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib142","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-12-3177","article-title":"Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab","volume":"19","author":"Schwartzberg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib143","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.breast.2013.07.037","article-title":"Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.bbrc.2026.154292_bib144","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-014-3015-6","article-title":"Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study","volume":"146","author":"Clemons","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2026.154292_bib145","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","article-title":"Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer","volume":"29","author":"Rugo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib146","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","article-title":"A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer","volume":"137","author":"Johnston","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2026.154292_bib147","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib148","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.21873\/anticanres.12983","article-title":"Blocking Interleukin-6 and Interleukin-8 signaling inhibits cell viability, colony-forming activity, and cell migration in human triple-negative breast cancer and pancreatic cancer cells","volume":"38","author":"Fu","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib149","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mc.23270","article-title":"Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells","volume":"60","author":"Alraouji","year":"2021","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbrc.2026.154292_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15584","article-title":"Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration","volume":"8","author":"Jayatilaka","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154292_bib151","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10637-018-0672-z","article-title":"A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-beta","volume":"36","author":"Yam","year":"2018","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.bbrc.2026.154292_bib152","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1111\/jcmm.13727","article-title":"Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1\/FGF1\/HGF signalling pathway","volume":"22","author":"Chen","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib153","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/path.4324","article-title":"MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2","volume":"232","author":"He","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2026.154292_bib154","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1471-2407-12-192","article-title":"Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2","volume":"12","author":"Wu","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nbt.2021.05.003","article-title":"Development of antibodies against the notch ligand Delta-Like-1 by phage display with activity against breast cancer cells","volume":"64","author":"Sales-Dias","year":"2021","journal-title":"New Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154292_bib156","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809266","article-title":"Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy","volume":"11","author":"Uribesalgo","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib157","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2026.154292_bib158","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","article-title":"Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer","volume":"8","author":"Han","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib159","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2026.154292_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020565","article-title":"Potential therapeutic strategies for lung and breast cancers through understanding the anti-angiogenesis resistance mechanisms","volume":"21","author":"Ramadan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib161","doi-asserted-by":"crossref","first-page":"326","DOI":"10.12688\/f1000research.11771.1","article-title":"The role of tumor microenvironment in resistance to anti-angiogenic therapy","volume":"7","author":"Ma","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.bbrc.2026.154292_bib162","first-page":"1675","article-title":"Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors","volume":"7","author":"Dey","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib163","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/15384047.2017.1294288","article-title":"Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry","volume":"18","author":"Sun","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib164","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091489","article-title":"Escaping antiangiogenic therapy: strategies employed by cancer cells","volume":"17","author":"Pinto","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib166","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib167","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbcan.2014.05.002","article-title":"Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.154292_bib168","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib169","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.bbrc.2026.154292_bib170","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154292_bib171","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib172","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/ijc.29163","article-title":"Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft","volume":"136","author":"Tan","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib173","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154292_bib174","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/mt.2013.112","article-title":"Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy","volume":"21","author":"Jha","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib175","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200712","article-title":"Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC","volume":"218","author":"Sharma","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib176","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.7150\/thno.55074","article-title":"FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts","volume":"11","author":"Wan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154292_bib177","doi-asserted-by":"crossref","first-page":"84248","DOI":"10.18632\/oncotarget.20539","article-title":"Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.154292_bib178","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2026.154292_bib179","doi-asserted-by":"crossref","first-page":"56126","DOI":"10.18632\/oncotarget.18445","article-title":"Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: implications for optimizing anti-angiogenic therapy","volume":"8","author":"De Francesco","year":"2017","journal-title":"Oncotarget"},{"issue":"Suppl 4","key":"10.1016\/j.bbrc.2026.154292_bib180","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/bcr2748","article-title":"Angiogenesis - still a worthwhile target for breast cancer therapy?","volume":"12","author":"Lord","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib181","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/fon.14.123","article-title":"Pericytes: a double-edged sword in cancer therapy","volume":"11","author":"Meng","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib182","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: current situation and future perspectives","volume":"41","author":"Zirlik","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.bbrc.2026.154292_bib183","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.celrep.2015.01.035","article-title":"Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2","volume":"10","author":"Keskin","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib184","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154292_bib185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2026.154292_bib186","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12885-018-4587-z","article-title":"TGF-beta signaling promotes tumor vasculature by enhancing the pericyte-endothelium association","volume":"18","author":"Zonneville","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib187","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","article-title":"Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis","volume":"25","author":"Zhou","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib188","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14450","article-title":"A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis","volume":"8","author":"Feng","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154292_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118094","article-title":"Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs","volume":"258","author":"Aslan","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2026.154292_bib190","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/878450","article-title":"MicroRNAs: promising new antiangiogenic targets in cancer","author":"Gallach","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bbrc.2026.154292_bib191","first-page":"13","article-title":"Phytochemicals and functional foods. Current situation and prospect for developing Countries","author":"Rodriguez","year":"2006","journal-title":"Seguran\u00e7a Alimentar e Nutricional"},{"key":"10.1016\/j.bbrc.2026.154292_bib192","doi-asserted-by":"crossref","first-page":"14556","DOI":"10.1002\/cam4.5984","article-title":"Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: a comprehensive review","volume":"12","author":"Sohel","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib193","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaim.2018.12.005","article-title":"Cytotoxic and apoptotic inducing activity of Amoora rohituka leaf extracts in human breast cancer cells","volume":"11","author":"Singh","year":"2020","journal-title":"J. Ayurveda Integr. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib194","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1615\/JEnvironPatholToxicolOncol.2019027318","article-title":"AgNPs from Nigella sativa control breast cancer: an in vitro study","volume":"38","author":"Rohini","year":"2019","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib195","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/tde.11.97","article-title":"Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer","volume":"2","author":"Royt","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bbrc.2026.154292_bib196","first-page":"1803","volume":"9","author":"Paul","year":"2021"},{"key":"10.1016\/j.bbrc.2026.154292_bib197","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3892\/or.2017.5652","article-title":"Ginsenoside Rd regulates the Akt\/mTOR\/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth","volume":"38","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib198","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.apjtm.2016.01.010","article-title":"Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice","volume":"9","author":"Zhang","year":"2016","journal-title":"Asian Pac. J. Tropical Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib199","first-page":"905","article-title":"Enterolactone suppresses proliferation, migration and metastasis of MDA-MB-231 breast cancer cells through inhibition of uPA induced plasmin activation and MMPs-Mediated ECM remodeling","volume":"18","author":"Mali","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.bbrc.2026.154292_bib200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2016.03.063","article-title":"Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer","volume":"781","author":"Zhao","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154292_bib201","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4174\/astr.2014.87.4.167","article-title":"Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells","volume":"87","author":"Kil","year":"2014","journal-title":"Ann. Surg. Treat Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib202","first-page":"641","article-title":"Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression","volume":"1","author":"Chakraborty","year":"2008","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib203","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/156652412802480826","article-title":"Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase\/Akt signaling pathway","volume":"12","author":"Kumar","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib204","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","article-title":"Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway","volume":"37","author":"Peng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib205","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mc.22602","article-title":"Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production","volume":"56","author":"Yu","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbrc.2026.154292_bib206","first-page":"89","article-title":"Mechanism of metastasis suppression by luteolin in breast cancer","volume":"10","author":"Cook","year":"2018","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.bbrc.2026.154292_bib207","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbrc.2017.06.140","article-title":"Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer","volume":"490","author":"Zang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154292_bib208","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14728222.2013.756869","article-title":"Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells","volume":"17","author":"Wang","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2026.154292_bib209","doi-asserted-by":"crossref","DOI":"10.1038\/srep35263","article-title":"New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment","volume":"6","author":"Yue","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1134\/S0006297908020132","article-title":"Inhibition of tumor specific angiogenesis by amentoflavone","volume":"73","author":"Guruvayoorappan","year":"2008","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.bbrc.2026.154292_bib211","first-page":"6685","article-title":"Amentoflavone induces anti-angiogenic and anti-metastatic effects through suppression of NF-kappaB activation in MCF-7 cells","volume":"35","author":"Chen","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib212","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10456-018-9630-9","article-title":"miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells","volume":"21","author":"Liang","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2026.154292_bib213","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41388-017-0089-8","article-title":"Hypoxia induces miR-153 through the IRE1alpha-XBP1 pathway to fine tune the HIF1alpha\/VEGFA axis in breast cancer angiogenesis","volume":"37","author":"Liang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154292_bib214","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41417-020-00240-1","article-title":"Correction: MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer","volume":"27","author":"Lu","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbrc.2026.154292_bib215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2017.03.032","article-title":"MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3","volume":"397","author":"Li","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154292_bib216","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3892\/or.2015.4529","article-title":"miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1alpha","volume":"35","author":"Wu","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib217","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.4161\/cc.20598","article-title":"MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF","volume":"11","author":"Zou","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2026.154292_bib218","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-824X-3-3","article-title":"Nanotechnology-mediated targeting of tumor angiogenesis","volume":"3","author":"Banerjee","year":"2011","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.bbrc.2026.154292_bib219","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.2147\/IJN.S223941","article-title":"Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications","volume":"14","author":"Darweesh","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2026.154292_bib220","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/cpr.12296","article-title":"Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR\/VEGFR-2-mediated pathway in breast cancer","volume":"49","author":"Balakrishnan","year":"2016","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bbrc.2026.154292_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120645","article-title":"Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles","volume":"269","author":"Shashni","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2026.154292_bib222","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.12659\/MSM.902538","article-title":"Nano-Hydroxyapatite-derived drug and gene Co-Delivery system for anti-angiogenesis therapy of breast cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bbrc.2026.154292_bib223","doi-asserted-by":"crossref","DOI":"10.3390\/nano14151294","article-title":"Chitosan nanoparticle-mediated delivery of curcumin suppresses tumor growth in breast cancer","volume":"14","author":"Mishra","year":"2024","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.bbrc.2026.154292_bib224","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.2147\/IJN.S523754","article-title":"Oxygen-generating biomimetic nano-herb system for synergistic therapy & pain relief in triple-negative breast cancer via HIF-1alpha\/VEGF pathway","volume":"20","author":"Cao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2026.154292_bib225","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1021\/acs.molpharmaceut.5c01740","article-title":"Molecular and antiangiogenic effects of paclitaxel-loaded nanoparticles: influence of the nanocarrier type","volume":"23","author":"Passos","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbrc.2026.154292_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071126","article-title":"Blocking tumoral angiogenesis VEGF\/VEGFR pathway: bevacizumab-20 years of therapeutic success and controversy","volume":"17","author":"Chitoran","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154292_bib227","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/genes15020177","article-title":"Cardiac and nephrological complications related to the use of antiangiogenic and anti-programmed cell death protein 1 receptor\/programmed cell death protein 1 ligand therapy","volume":"15","author":"Stachyra-Strawa","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbrc.2026.154292_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100576","article-title":"Two phase I studies of BI 836880, a vascular endothelial growth factor\/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors","volume":"7","author":"Le Tourneau","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbrc.2026.154292_bib230","article-title":"Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154292_bib231","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2(Hi) macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2026.154292_bib232","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13058-024-01942-2","article-title":"Cilengitide sensitivity is predicted by overall integrin expression in breast cancer","volume":"26","author":"Girnius","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154292_bib233","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","article-title":"Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models","volume":"13","author":"Rodriguez","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154292_bib234","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154292_bib235","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41523-021-00247-3","article-title":"Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis","volume":"7","author":"Xiao","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bbrc.2026.154292_bib236","first-page":"36","volume":"8","author":"Suryendu","year":"2025"},{"key":"10.1016\/j.bbrc.2026.154292_bib237","first-page":"945","article-title":"PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis","volume":"52","author":"Peng","year":"2018","journal-title":"Int. J. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.bbrc.2026.154402","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000}},{"DOI":"10.1016\/j.bbrc.2026.154402","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000}}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:20:57Z","timestamp":1788290457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26010569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":237,"alternative-id":["S0006291X26010569"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154292","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming tumor angiogenesis in breast cancer: Mechanisms, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154292"}}